BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · IEX Real-Time Price · USD
6.55
-0.12 (-1.80%)
At close: Jul 2, 2024, 4:00 PM
6.50
-0.05 (-0.76%)
After-hours: Jul 2, 2024, 7:24 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for BCRX stock have an average target of 14, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 113.74% from the current stock price of 6.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 7, 2024.
Analyst Ratings
The average analyst rating for BCRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +83.21% | May 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +358.02% | May 7, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +129.01% | May 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +83.21% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +83.21% | Jan 8, 2024 |
Financial Forecast
Revenue This Year
410.62M
from 331.41M
Increased by 23.90%
Revenue Next Year
484.66M
from 410.62M
Increased by 18.03%
EPS This Year
-0.61
from -1.18
EPS Next Year
-0.33
from -0.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 428.5M | 537.8M | 685.4M | 824.6M | 949.8M |
| Avg | 410.6M | 484.7M | 570.6M | 690.0M | 781.5M |
| Low | 387.1M | 375.3M | 407.7M | 542.5M | 598.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.3% | 31.0% | 41.4% | 44.5% | 37.7% |
| Avg | 23.9% | 18.0% | 17.7% | 20.9% | 13.3% |
| Low | 16.8% | -8.6% | -15.9% | -4.9% | -13.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.54 | -0.08 | 0.45 | 1.31 | 2.10 |
| Avg | -0.61 | -0.33 | 0.07 | 0.61 | 0.96 |
| Low | -0.73 | -0.80 | -0.70 | 0.05 | 0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,650.7% | 243.1% |
| Avg | - | - | - | 716.3% | 56.3% |
| Low | - | - | - | -34.6% | -56.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.